|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09997 KANGJI MEDICAL
Nominal 
6.040 +0.090 (+1.513%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 926,023 | 17.760% | 786,367 | 690,263 | 511,490 | 503,467 |
| Cost of Sales | (184,824) | 22.303% | (151,120) | (127,337) | (80,020) | (80,292) |
| Gross Profit | 741,199 | 16.679% | 635,247 | 562,926 | 431,470 | 423,175 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (1,064) | -- | 1,054 | (614) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 588,771 | 4.551% | 563,144 | 534,497 | 310,075 | 391,194 | |
| Taxation | (136,476) | 33.839% | (101,970) | (77,708) | (50,925) | (64,459) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 51,726 | 194.550% | 17,561 | 0 | (8,854) | (120,291) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 504,021 | 5.282% | 478,735 | 456,789 | 250,296 | 206,444 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (89,575) | 31.480% | (68,128) | (33,092) | (11,735) | (12,560) |
| Depreciation & Amortisation | 32,954 | 52.346% | 21,631 | 11,860 | 8,204 | 6,845 |
| Directors' Emoluments | 9,302 | 20.274% | 7,734 | 7,756 | 8,204 | 867 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 43.080 | 8.706% | 39.630 | 37.310 | 26.270 | 20.110 |
| DPS (cts) | 140.000 | -- | 18.450 | 14.610 | 3.702 | -- |
| Dividend Payout Ratio (%) | 324.977% | -- | 46.556% | 39.158% | 14.093% | -- |
| Cash flow per share ($) | 0.359 | -- | 0.264 | 0.356 | 0.232 | 0.317 |
| NBV per share ($) | 2.999 | -- | 2.766 | 2.617 | 2.345 | -- |
| Remarks: | Real time quote last updated: 19/11/2024 10:04 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 285,847,000 |
| %Change | 11.895% |
| EPS / (LPS) | RMB 0.244 |
| NBV Per Share (¥) | RMB 1.945 |